[go: up one dir, main page]

AR130848A1 - Compuestos heterocíclicos con capacidad para activar el receptor sting - Google Patents

Compuestos heterocíclicos con capacidad para activar el receptor sting

Info

Publication number
AR130848A1
AR130848A1 ARP230102835A ARP230102835A AR130848A1 AR 130848 A1 AR130848 A1 AR 130848A1 AR P230102835 A ARP230102835 A AR P230102835A AR P230102835 A ARP230102835 A AR P230102835A AR 130848 A1 AR130848 A1 AR 130848A1
Authority
AR
Argentina
Prior art keywords
activate
capacity
heterocyclic compounds
sting receptor
compounds
Prior art date
Application number
ARP230102835A
Other languages
English (en)
Inventor
Keith Andrew Newton Graham
Sebastian Carotta
Georg Dahmann
Cdrickx Godbout
Sandra Ruth Handschuh
Herbert Nar
Thorsten Oost
Ulrich Reiser
Esther Schmidt
Matthias Treu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR130848A1 publication Critical patent/AR130848A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos de fórmula (1) que son capaces de activar a STING (Estimulador de Genes de Interferón, por sus siglas en inglés). La presente invención además se relaciona con composiciones farmacéuticas que comprenden por lo menos un compuesto de fórmula (1), así como también con el uso de estos compuestos o las composiciones farmacéuticas como medicamento, por ejemplo, para tratar cáncer en caninos o felinos, o como adyuvantes para vacunas.
ARP230102835A 2022-10-26 2023-10-24 Compuestos heterocíclicos con capacidad para activar el receptor sting AR130848A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22203741 2022-10-26

Publications (1)

Publication Number Publication Date
AR130848A1 true AR130848A1 (es) 2025-01-22

Family

ID=83996638

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102835A AR130848A1 (es) 2022-10-26 2023-10-24 Compuestos heterocíclicos con capacidad para activar el receptor sting

Country Status (10)

Country Link
US (1) US20240174642A1 (es)
EP (1) EP4608819A1 (es)
KR (1) KR20250093392A (es)
CN (1) CN120091996A (es)
AR (1) AR130848A1 (es)
AU (1) AU2023370101A1 (es)
CO (1) CO2025004875A2 (es)
MX (1) MX2025004813A (es)
TW (1) TW202432545A (es)
WO (1) WO2024089008A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
JP7566731B2 (ja) * 2018-07-03 2024-10-15 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
TWI855000B (zh) 2018-10-11 2024-09-11 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白

Also Published As

Publication number Publication date
CO2025004875A2 (es) 2025-06-16
AU2023370101A1 (en) 2025-06-05
TW202432545A (zh) 2024-08-16
EP4608819A1 (en) 2025-09-03
WO2024089008A1 (en) 2024-05-02
MX2025004813A (es) 2025-06-02
KR20250093392A (ko) 2025-06-24
CN120091996A (zh) 2025-06-03
US20240174642A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
CO2025005150A2 (es) Compuestos heterocíclicos con capacidad para activar el receptor sting
SA520412278B1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات جين أس أوه أس 1
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
DOP2023000285A (es) Restos de administración terapéutica novedosos y usos de estos
CL2018001484A1 (es) Dinucleotidas de purino ciclico como moduladores de estimulador de genes de interferon (sting).
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
PE20181045A1 (es) Compuestos utiles como inmunomoduladores
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
UY31072A1 (es) Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
UY31281A1 (es) Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
MX2021015188A (es) Moduladores de nueva generacion del estimulador de genes de interferon (sting).
UA116469C2 (uk) Похідні тамоксифену для лікування новоутворень, особливо з високим рівнем білка her2
PA8807801A1 (es) Inhibidores de cinesina como productos terapeuticos para el cancer
PA8576101A1 (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
MX2022007178A (es) Compuestos heterociclicos como moduladores del estimulador de genes de interferon (sting).
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CO2018011819A2 (es) Inhibidores del potenciador del homólogo zeste 2
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MY197561A (en) Composition for increasing expression of pgc-1?
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
BR112022008039A2 (pt) Compostos de 4-amino-imidazoquinolina e usos relacionados
DOP2022000203A (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52